MA39823A - Dérivés de pyridine macrocyclique - Google Patents

Dérivés de pyridine macrocyclique

Info

Publication number
MA39823A
MA39823A MA039823A MA39823A MA39823A MA 39823 A MA39823 A MA 39823A MA 039823 A MA039823 A MA 039823A MA 39823 A MA39823 A MA 39823A MA 39823 A MA39823 A MA 39823A
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
macrocyclic
macrocyclic pyridine
derivatives
pyridine
Prior art date
Application number
MA039823A
Other languages
English (en)
Inventor
Didier Jean-Claude Berthelot
Gaston Stanislas Marcella Diels
Lieven Meerpoel
Bruno Schoentjes
François Maria Sommen
Matthias Luc Aimé Versele
Marcel Viellevoye
Marc Willems
Berthold Wroblowski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA39823A publication Critical patent/MA39823A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA039823A 2014-04-03 2015-04-01 Dérivés de pyridine macrocyclique MA39823A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163442 2014-04-03
EP14183823 2014-09-05

Publications (1)

Publication Number Publication Date
MA39823A true MA39823A (fr) 2018-01-09

Family

ID=52781118

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039823A MA39823A (fr) 2014-04-03 2015-04-01 Dérivés de pyridine macrocyclique

Country Status (22)

Country Link
US (1) US20170022201A1 (fr)
EP (1) EP3126365B1 (fr)
JP (1) JP6420362B2 (fr)
KR (1) KR102390274B1 (fr)
CN (1) CN106132964B (fr)
AU (1) AU2015239100B2 (fr)
BR (1) BR112016022700B1 (fr)
CA (1) CA2942751C (fr)
CL (1) CL2016002495A1 (fr)
EA (1) EA029758B1 (fr)
ES (1) ES2665797T3 (fr)
IL (1) IL248001B (fr)
MA (1) MA39823A (fr)
MX (1) MX369799B (fr)
MY (1) MY185500A (fr)
NZ (1) NZ725406A (fr)
PE (1) PE20161365A1 (fr)
PH (1) PH12016501962B1 (fr)
SG (1) SG11201608241UA (fr)
UA (1) UA118120C2 (fr)
WO (1) WO2015150557A1 (fr)
ZA (1) ZA201606768B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998885C (fr) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Bibliotheques de composes macrocycliques contenant heteroaryle et procedes pour leur fabrication et leur utilisation
ES2821400T3 (es) 2016-02-19 2021-04-26 Sprint Bioscience Ab Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes
TWI721104B (zh) 2016-02-19 2021-03-11 瑞典商斯普林特生物科技公司 6‐芳基或6‐雜芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX394210B (es) * 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
EP3601236A1 (fr) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
CA3066499A1 (fr) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. Bibliotheques de composes macrocycliques contenant de la pyridine et leurs procedes de preparation et d'utilisation
TW202325302A (zh) 2017-08-23 2023-07-01 瑞典商斯普林特生物科技公司 吡啶胺-吡啶酮及嘧啶胺-吡啶酮化合物
SI3672962T1 (sl) 2017-08-23 2022-06-30 Sprint Bioscience Ab Morfolinilpiridonske spojine
SI3672967T1 (sl) 2017-08-23 2022-04-29 Sprint Bioscience Ab Spojine azaindolilpiridona in diazaindolilpiridona
JP7199737B2 (ja) 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ ピリジルピリドン化合物
WO2020047208A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
WO2020047239A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE ανβ6
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
CN114555609A (zh) * 2019-08-16 2022-05-27 英夫拉索姆有限公司 用作nlrp3抑制剂的大环磺酰胺衍生物
CN113845521B (zh) * 2021-08-31 2024-06-18 中原工学院 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227755A1 (en) * 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2004078682A2 (fr) * 2003-03-05 2004-09-16 Irm Llc Composes cycliques et compositions servant d'inhibiteurs de proteines-kinases
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
MXPA06007018A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US8778919B2 (en) 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
WO2007058627A1 (fr) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Derives de pyrimidine a liaison oxygene
CA2687909C (fr) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones et aza-indolin-2-ones
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8318929B2 (en) 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
JP2011522865A (ja) 2008-06-13 2011-08-04 ノバルティス アーゲー Ia心不全および癌の治療に有用なプロテインキナーゼd阻害剤としての2,4’−ビピリジニル化合物

Also Published As

Publication number Publication date
PE20161365A1 (es) 2016-12-17
CA2942751A1 (fr) 2015-10-08
PH12016501962A1 (en) 2017-01-09
KR102390274B1 (ko) 2022-04-22
ES2665797T3 (es) 2018-04-27
AU2015239100B2 (en) 2019-06-27
KR20160140739A (ko) 2016-12-07
UA118120C2 (uk) 2018-11-26
BR112016022700B1 (pt) 2022-01-11
BR112016022700A2 (fr) 2017-08-15
MX369799B (es) 2019-11-21
US20170022201A1 (en) 2017-01-26
IL248001B (en) 2018-11-29
EA201692000A1 (ru) 2017-01-30
CA2942751C (fr) 2023-03-21
EP3126365A1 (fr) 2017-02-08
JP2017509685A (ja) 2017-04-06
AU2015239100A1 (en) 2016-09-29
EP3126365B1 (fr) 2018-01-10
JP6420362B2 (ja) 2018-11-07
CN106132964B (zh) 2019-07-19
MX2016012994A (es) 2016-12-07
SG11201608241UA (en) 2016-10-28
ZA201606768B (en) 2018-11-28
WO2015150557A1 (fr) 2015-10-08
CL2016002495A1 (es) 2017-02-24
CN106132964A (zh) 2016-11-16
PH12016501962B1 (en) 2017-01-09
KR102390274B9 (ko) 2023-03-03
MY185500A (en) 2021-05-19
NZ725406A (en) 2022-08-26
EA029758B1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MA39823A (fr) Dérivés de pyridine macrocyclique
CL2016002461A1 (es) Derivados macrocíclicos de pirimidina
DK3319956T3 (da) Substituerede oxopyridinderivater
LT3204359T (lt) Tetrahidroizochinolino dariniai
EP3319969A4 (fr) Polymorphe de macrocycle de diaryle
MA54254A (fr) Dérivés de benzodiazépine cytotoxique
DK3168219T3 (da) Pyridonderivat med tetrahydropyranylmethylgruppe
HUE048321T2 (hu) Karabazol származékok
EP3457851A4 (fr) Dérivés de sobétirome
LT3402792T (lt) Chinolin-2-ono dariniai
DK3231803T3 (da) Dihydroindolizinonderivat
LT3371168T (lt) Indolin-2-ono dariniai
MA41790A (fr) Dérivé de morphinane
PT3131898T (pt) Derivados de fluoroalquilfluoreno
HRP20180826T1 (hr) Klizni ležajevi za konstrukcije
EP3309163A4 (fr) Dérivé de dihydropyrrolopyrazole substitué
EP3554637A4 (fr) Dérivés de spiropipéridine
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
FR3025199B1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide
IL249210A0 (en) A pyridine derivative
IL248900A0 (en) Pyrazine derivatives
PT3228616T (pt) Derivados de piridina
CL2015000871S1 (es) Pieza de rodillo